Immunotoxins

Herausgegeben:Frankel, Arthur E.

• Broschiertes Buch

Produktbeschreibung

Where do you begin to look for a recent, authoritative article on the diagnosis or management of a particular malignancy? The few general oncology textbooks are generally out of date. Single papers in specialized journals are informative but seldom comprehensive; these are more often preliminary reports on a very limited number of patients. Certain general journals frequently publish good indepth reviews of cancer topics, and published symposium lectures are often the best overviews available. Un fortunately, these reviews and supplements appear sporadically, and the reader can never be sure when a topic of special interest will be covered. Cancer Treatment and Research is a series of authoritative volumes which aim to meet this need. It is an attempt to establish a critical mass of oncology literature covering virtually all oncology topics, revised frequently to keep the coverage up-to-date, easily available on a single library shelf or by a single personal subscription. We haveapproached the problem in the following fashion. First, by dividing the oncology literature into specific subdivisions such as lung cancer, genitourinary cancer, pediatric oncology, etc. Second, by asking eminent authorities in each of these areas to edit a volume on the specific topic on an annual or biannual basis. Each topic and tumor type is covered in a volume appearing frequently and predictably, discussing current diagnosis, staging, markers, all forms of treatment modalities, basic biology, and more.

---

Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.

Produktdetails

• Cancer Treatment and Research 37
• Verlag: Springer / Springer US / Springer, Berlin
• Artikelnr. des Verlages: 978-1-4612-8419-2
• Softcover reprint of the original 1st ed. 1988
• Seitenzahl: 588
• Erscheinungstermin: 27. September 2011
• Englisch
• Abmessung: 240mm x 160mm x 32mm
• Gewicht: 926g
• ISBN-13: 9781461284192
• ISBN-10: 1461284198
• Artikelnr.: 39679997

Inhaltsangabe

1. Introduction.- I. Toxin Structure.- 2. Toxin structure.- 3. Structure-activity relationships in diphtheria toxin and Pseudomonas aeruginosa exotoxin A.- II. How Toxins Work.- 4. How protein toxins enter and kill cells.- 5. Mechanism of action of ricin and related toxins on the inactivation of eukaryotic ribosomes.- III. Toxin Selection and Modification.- 6. Toxin selection and modification - Overview.- 7. Toxin selection and modification: Utilization of the A chain of ricin.- 8. Genetic engineering of immunotoxins.- 9. Diphtheria-related peptide hormone gene fusions: A molecular genetic approach to chimeric toxin development.- 10. Immunotoxins containing ricin.- 11. Pseudomonas exotoxin - Immunotoxins.- 12. Immunotoxins containing single chain ribosome-inactivating proteins.- IV. Covalent Linking Agents.- 13. Antibody-toxin conjugation.- 14. Effect of chemical linkage upon the stability and cytotoxic activity of A chain immunotoxins.- V. Antibody Selection.- 15. Immunotoxins: Selection of cell-surface antigens and their corresponding monoclonal antibodies.- VI. Nonantibody Ligands.- 16. Hormone, lectin and toxin-toxin conjugates.- 17. Growth factors and other ligands.- VII. Purification and Chemical Characterization.- 18. Purification and biochemical characterization of immunotoxins.- VIII. Enhancers.- 19. Immunotoxin enhancers.- 20. Enhancement of immunotoxin action: Manipulation of the cellular routing of proteins.- IX. Cytotoxicity.- 21. Methods for quantifying immunotoxin efficacy.- 22. Kinetic analysis of cytotoxicity.- 23. Isolation and analysis of somatic cell mutants resistant to toxin conjugates.- X. Animal Studies.- 24. Immunotoxin therapy: Assessment by animal models.- 25. Prevention of carbohydrate-mediated clearance of ricin-containing immunotoxinsby the liver.- 26. Human immune response to immunotoxins.- XI. Clinical Studies.- 27. Treatment of leukemia patients with T101 ricin A chain immunotoxins.- 28. Clinical studies: Solid tumors.- 29. Immunotoxins for ex vivo bone marrow purging in human bone marrow transplantation.- 30. Conclusion.